DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects

NCT ID: NCT04086797

Last Updated: 2023-11-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 178 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-11
• Study Completion Date: 2021-04-08

Brief Summary

The main study objective is to evaluate the efficacy of IQP-AE-103 in reducing body weight in overweight and moderately obese subjects, in the context of an energy restricted diet. Further objectives are to evaluate the beneficial potential of IQP-AE-103 on waist circumference, blood pressure and blood glucose and lipid levels, quality of life, as well as its safety and tolerability

Detailed Description

Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. Obesity is a substantial public health problem throughout the world, with the prevalence increasing rapidly in numerous developing and developed nations. In 2014, about 13% of the world's adult populations were obese and 39% were overweight. The worldwide prevalence of obesity has more than doubled in over 30 years (WHO, 2016). Obesity and overweight pose major risks for serious diseases, such as dyslipidemia, type 2 diabetes, hypertension, coronary heart disease and stroke (Haslam & James 2005) and average life expectancy is reduced in obese people (Fontaine et al. 2003). Dietary fat plays a major role in the development of overeating and obesity (Bray et al. 2004); thus fat uptake should be a main target to reduce energy intake and achieve a loss of body weight (Svendsen & Tonstad, 2011). It has been shown that nutrients such as protein and fibre reduce lipid absorption (e.g. Chong et al., 2014; Hosomi et al., 2010; Tsujita et al., 2007). The main components of the IQP-AE-103 are okra (Abelmoschus esculentus (L.) Moench) pod powder and inulin. Okra pod powder contains a combination of dietary fibre and protein, which may have an important role in fat binding (Kumar et al., 2013). Dehydrated powder derived from okra pod has further been shown to have substantial swelling capabilities when added to water (Bakre & Jaiyeaob, 2009), which can potentially provide satiety effects. Inulin is a fermentable fructan, derived from plants such as asparagus, garlic, leak, onion etc.

and serves as an important source of soluble dietary fibre (Jaundzeikare and Beitane, 2014), to further enhance the effect of fat binding. The efficacy of IQP-AE-103 in body weight reduction during intake of 12 weeks has been shown recently in a clinical trial with 108 overweight and moderately obese subjects (Uebelhack et al., 2019). The present study aims at a broader evaluation of the beneficial effects of IQP-AE-103 for use in weight management, including its impact on waist circumference, blood pressure and blood glucose and lipid levels as well as quality of life, in overweight and moderately obese subjects.

Conditions

Overweight; Obesity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

IQP-AE-103

2 capsules after 3 main meals per day (total 1980 mg)

Group Type: EXPERIMENTAL

IQP-AE-103

Intervention Type: DIETARY_SUPPLEMENT

1980 mg

Placebo

2 capsules after 3 main meals per day

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Interventions

IQP-AE-103

1980 mg

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Placebo

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

1. Men and women from 18 to 70 years old

2. Body mass index (BMI) 25 kg/m2 - 34.9 kg/m2

3. Having at least one of the following traits:

• waist circumference ≥ 94 cm in men and ≥ 80 cm in women
• triglyceride levels ≥ 150 mg/dL (1.7 mmol/L)
• high-density lipoprotein cholesterol (HDL-C) levels: ≤ 40 mg/dL (1.0 mmol/L) in men and ≤ 50 mg/dL (1.3 mmol/L) in women
• blood pressure (BP), average value of the last two values of the triplicate measurement: systolic BP ≥ 130 mmHg, diastolic BP ≥ 85 mmHg
• fasting blood glucose ≥ 100 mg/dL

4. Desire to lose weight

5. Readiness and ability to complete the study, according to investigator's judgement following the screening interview

6. Accustomed to regular daily consumption of 3 main meals (breakfast, lunch, dinner)

7. Consistent and stable body weight in the last 3 months prior to V1 (less than 5% self-reported change)

8. Subject's agreement to comply with study procedures, in particular:

• to adhere to diet recommendation during the study
• to take IP as recommended
• to avoid the use of other weight loss and/or management products and/or programs during the study
• to keep the habitual level of physical activity
• to complete the subject diary and study questionnaires

9. Women of childbearing potential:

• commitment to use contraception methods
• negative pregnancy testing (beta human chorionic gonadotropin test in urine) at V1

10. Readiness not to participate in another clinical study during this study Participation is based upon written informed consent by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.

• clinically significant or
• >2x upper limit of normal, unless the deviation is justified by a previously known not clinically relevant condition (e.g. Gilbert's syndrome)

7. Any electronic medical implant

8. Regular medication and/or supplementation and/or treatment within the last 3 months prior to V1 and during the study:

• that could influence body weight (e.g. systemic corticosteroids)
• that could influence gastrointestinal functions (e.g. laxatives, opioids, anticholinergics etc.) as per investigator judgement
• for weight management (e.g. fat binder, carbohydrate/ starch blocker, fat burner, satiety products, acupuncture etc.)
• that could influence lipid levels, blood pressure and/or glycemic control

9. Self-reported smoking cessation within 6 months prior to V1 and/or during the study (regular smoking during the study at the same level as prior to the study is allowed)

10. Women of child-bearing potential: pregnancy or nursing

11. History of or current abuse of drugs, alcohol or medication

12. Participation in another study during the last 30 days prior to V1

13. Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures

Exclusion Criteria

1. Known allergy or hypersensitivity to the components of the investigational product or source plants

2. Pathological electrocardiogram (ECG) at V1

3. History and/or presence of clinically significant condition/ disorder, which per investigator's judgement could interfere with the results of the study or the safety of the subject, e.g.:

• untreated or unstable thyroid gland disorder
• hypertension (regular systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg)
• acute or chronic gastrointestinal (GI) disease or digestion/ absorption disorders (e.g. inflammatory bowel disease, coeliac disease, pancreatitis etc.)
• diabetes mellitus
• any other relevant serious organ or systemic diseases

4. Significant surgery within the last 6 months prior to V1 or planned within the study period:

• GI surgery
• liposuction

5. History of eating disorders like bulimia, anorexia nervosa, binge-eating within the last 12 months prior to V1

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Analyze & Realize

NETWORK

Sponsor Role: collaborator

Perrigo CSCI

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ralf Uebelhack, MD

Role: PRINCIPAL_INVESTIGATOR

Analyze & Realize

Locations

analyze & realize GmbH

Berlin, , Germany

Countries

Germany

References

Uebelhack R, Bongartz U, Seibt S, Bothe G, Chong PW, De Costa P, Wszelaki N. Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects. J Obes. 2019 Feb 3;2019:3412952. doi: 10.1155/2019/3412952. eCollection 2019.

Reference Type: BACKGROUND

PMID: 30863632 (View on PubMed)

Other Identifiers

PERI/020918

Identifier Type: -

Identifier Source: org_study_id